The use of palmitoylethanolamide in backpain has been reported by Lambert in 2002, but was already known in the scientific community before that date. Now we found clear proof of such knowledge, which is important for the history around this very interesting compound.
In 2001 it was also apperently already known how useful palmitoylethanolamide was in low back pain. Quote:
PEA, a putative endocannabinoid, demonstrates some cannabinoid properties but does not
bind to recombinant human cannabinoid receptors. However, anti-inflammatory activity in
rodents has lead to clinical trials in chronic back pain as the drug “Palmidrol”
Anita Holdcroft, Parind Patel. Cannabinoids and pain relief September 2001, Vol. 1, No. 1 , Pages 92-99 (doi:10.1586/14737184.108.40.206)